• 2102 Citations
  • 23 h-Index
20012019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Erik K Henricson is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 2 Similar Profiles
Duchenne Muscular Dystrophy Medicine & Life Sciences
Natural History Medicine & Life Sciences
Glucocorticoids Medicine & Life Sciences
Clinical Trials Medicine & Life Sciences
Biomarkers Medicine & Life Sciences
Walking Medicine & Life Sciences
Outcome Assessment (Health Care) Medicine & Life Sciences
Therapeutics Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2001 2019

  • 2102 Citations
  • 23 h-Index
  • 40 Article
  • 2 Review article
  • 1 Conference contribution
  • 1 Comment/debate

Disease-specific and glucocorticoid-responsive serum biomarkers for Duchenne Muscular Dystrophy

Hathout, Y., Liang, C., Ogundele, M., Xu, G., Tawalbeh, S. M., Dang, U. J., Hoffman, E. P., Gordish-Dressman, H., Conklin, L. S., van den Anker, J. N., Clemens, P. R., Mah, J. K., Henricson, E. K. & McDonald, C. M., Dec 1 2019, In : Scientific reports. 9, 1, 12167.

Research output: Contribution to journalArticle

Open Access
Duchenne Muscular Dystrophy
Glucocorticoids
Biomarkers
Serum
Cell Adhesion
1 Citation (Scopus)

Eteplirsen treatment attenuates respiratory decline in ambulatory and non-ambulatory patients with duchenne muscular dystrophy

Khan, N., Eliopoulos, H., Han, L., Kinane, T. B., Lowes, L. P., Mendell, J. R., Gordish-Dressman, H., Henricson, E. K. & McDonald, C. M., Jan 1 2019, In : Journal of Neuromuscular Diseases. 6, 2, p. 213-225 13 p.

Research output: Contribution to journalArticle

Open Access
Duchenne Muscular Dystrophy
Natural History
Vital Capacity
Research
Glucocorticoids
1 Citation (Scopus)

Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy

the Duchenne Muscular Dystrophy Regulatory Science Consortium (D-RSC), Jan 1 2019, In : Journal of Pharmacokinetics and Pharmacodynamics.

Research output: Contribution to journalArticle

Duchenne Muscular Dystrophy
Clinical Protocols
Rare Diseases
Uncertainty
Clinical Trials
7 Citations (Scopus)

Longitudinal pulmonary function testing outcome measures in Duchenne muscular dystrophy: Long-term natural history with and without glucocorticoids

CINRG investigators for PubMed, Jan 1 2018, (Accepted/In press) In : Neuromuscular Disorders.

Research output: Contribution to journalArticle

Duchenne Muscular Dystrophy
Natural History
Glucocorticoids
Vital Capacity
Outcome Assessment (Health Care)
3 Citations (Scopus)

Placebo-controlled Phase 2 Trial of Drisapersen for Duchenne Muscular Dystrophy

McDonald, C. M., Wong, B., Flanigan, K. M., Wilson, R., de Kimpe, S., Lourbakos, A., Lin, Z. & Henricson, E. K., Jan 1 2018, (Accepted/In press) In : Annals of Clinical and Translational Neurology.

Research output: Contribution to journalArticle

Duchenne Muscular Dystrophy
Placebos
Walking
PRO051
Respiratory Function Tests